The worldwide pharmaceutical industry is responsible for bringing medications to patients. This market has exploded in recent years, with pharma revenues worldwide totaling 1.27 trillion US dollars in 2020. As part of this growth we are seeing more and more interest in developing medicines for rare neurodevelopmental disorders like Fragile X syndrome.
Recently we had a great opportunity to encourage pharma and biotech scientists to focus their resources on Fragile X at the Neurodevelopmental Drug Development Summit. This two-day industry-dedicated forum brought together key leaders from large pharma, biotech and academia to present to the international pharmaceutical community. The goal was to advance treatments across neurodevelopmental disorders, and in particular Fragile X, Angelman syndrome, and Prader-Willi syndrome.
These key industry leaders are working together to develop new outcome measures that target the neurodevelopmental disease, driving design innovation across disease-specific clinical trials to improve the lives of patients.
FRAXA president and co-founder, Katie Clapp was one of three patient advocacy leaders invited to kick off the meeting with a presentation on Fragile X, and FRAXA Scientific Advisor, Dr. Elizabeth Berry-Kravis discussed lessons learned from clinical trials in Fragile X Syndrome. Participants also heard from our pharma partners STALICLA, Autifony Therapeutics, and Anavex about their Fragile X treatment development programs. We look forward to future opportunities like this to showcase Fragile X research progress.
